Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data

Ngo, Tam N.M.; Le, Trang Thi Bich; Thoa, Le Thi Bich; Bychkov, Andrey; Oishi, Naoki; Jung, Chan Kwon; Hassell, Lewis; Kakudo, Kennichi; Vuong, Huy Gia

doi:10.1007/s12022-021-09692-z

Cited by 9 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This led to the conclusion of there being very few common mutations and a large genomic divergence between the two components challenging the concept of tumor progression from DTC to ATC [ 31 ]. From the clinical point of view, a recent retrospective multicenter and SEER database study on 642 primary (i.e., tumors with no DTC component at diagnosis) and 47 secondary ATC (i.e., tumors with a DTC component at diagnosis), found no statistical differences in terms of demographic, clinical manifestations and patient survival and a more frequent BRAF mutation as compared with RAS mutation in secondary tumors [ 32 ]. However, it must be pointed out that identification of “transformed” ATC requires the knowledge of the detailed clinical history of the patient as well as the detailed pathology assessment of the tumor which may not be optimal in a very large database.…”

Section: Pathology and Biology: How Do We Understand The Aggressivene...mentioning

confidence: 99%

Anaplastic Thyroid Carcinoma: An Update

Jannin

Escande

Ghuzlan

et al. 2022

Cancers

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is a rare and undifferentiated form of thyroid cancer. Its prognosis is poor: the median overall survival (OS) of patients varies from 4 to 10 months after diagnosis. However, a doubling of the OS time may be possible owing to a more systematic use of molecular tests for targeted therapies and integration of fast-track dedicated care pathways for these patients in tertiary centers. The diagnostic confirmation, if needed, requires an urgent biopsy reread by an expert pathologist with additional immunohistochemical and molecular analyses. Therapeutic management, defined in multidisciplinary meetings, respecting the patient’s choice, must start within days following diagnosis. For localized disease diagnosed after primary surgical treatment, adjuvant chemo-radiotherapy is recommended. In the event of locally advanced or metastatic disease, the prognosis is very poor. Treatment should then involve chemotherapy or targeted therapy and decompressive cervical radiotherapy. Here we will review current knowledge on ATC and provide perspectives to improve the management of this deadly disease.

show abstract

Section: Pathology and Biology: How Do We Understand The Aggressivene...mentioning

confidence: 99%

Anaplastic Thyroid Carcinoma: An Update

Jannin

Escande

Ghuzlan

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…ATC is usually observed in elderly patients, mostly aged over 60 years, whose median overall survival (OS) is a few months from the diagnosis [1][2][3][4]. It may originate as a primary tumor, i.e., ex novo in individuals without a history of thyroid neoplasms, or as a secondary tumor, arising from preexisting differentiated (DTC) or poorly differentiated (PDTC) thyroid carcinomas [1,4,5]. A recent study analyzing the Surveillance, Epidemiology, and End Result (SEER) database reported that ATC represents 1% of all thyroid cancers and that secondary ATC accounts for only 3.7% of all ATC [5].…”

Section: Introductionmentioning

confidence: 99%

“…It may originate as a primary tumor, i.e., ex novo in individuals without a history of thyroid neoplasms, or as a secondary tumor, arising from preexisting differentiated (DTC) or poorly differentiated (PDTC) thyroid carcinomas [1,4,5]. A recent study analyzing the Surveillance, Epidemiology, and End Result (SEER) database reported that ATC represents 1% of all thyroid cancers and that secondary ATC accounts for only 3.7% of all ATC [5]. Conversely, studies of single institutional experiences with small to moderate case series described an incidence of secondary ATC varying from 5 to 50% of all ATC [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

“…A recent study analyzing the Surveillance, Epidemiology, and End Result (SEER) database reported that ATC represents 1% of all thyroid cancers and that secondary ATC accounts for only 3.7% of all ATC [5]. Conversely, studies of single institutional experiences with small to moderate case series described an incidence of secondary ATC varying from 5 to 50% of all ATC [5][6][7][8]. At any rate, patients with primary and secondary ATC share very similar clinical features and overall survival [4,5,9].…”

Section: Introductionmentioning

confidence: 99%

“…Conversely, studies of single institutional experiences with small to moderate case series described an incidence of secondary ATC varying from 5 to 50% of all ATC [5][6][7][8]. At any rate, patients with primary and secondary ATC share very similar clinical features and overall survival [4,5,9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells

Baldini,

Cardarelli,

Campese

et al. 2024

IJMS

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is an extremely difficult disease to tackle, with an overall patient survival of only a few months. The currently used therapeutic drugs, such as kinase inhibitors or immune checkpoint inhibitors, can prolong patient survival but fail to eradicate the tumor. In addition, the onset of drug resistance and adverse side-effects over time drastically reduce the chances of treatment. We recently showed that Twist1, a transcription factor involved in the epithelial mesenchymal transition (EMT), was strongly upregulated in ATC, and we wondered whether it might represent a therapeutic target in ATC patients. To investigate this hypothesis, the effects of harmine, a β-carboline alkaloid shown to induce degradation of the Twist1 protein and to possess antitumoral activity in different cancer types, were evaluated on two ATC-derived cell lines, BHT-101 and CAL-62. The results obtained demonstrated that, in both cell lines, harmine reduced the level of Twist1 protein and reverted the EMT, as suggested by the augmentation of E-cadherin and decrease in fibronectin expression. The drug also inhibited cell proliferation and migration in a dose-dependent manner and significantly reduced the anchorage-independent growth of both ATC cell lines. Harmine was also capable of inducing apoptosis in BHT-101 cells, but not in CAL-62 ones. Finally, the activation of PI3K/Akt signaling, but not that of the MAPK, was drastically reduced in treated cells. Overall, these in vitro data suggest that harmine could represent a new therapeutic option for ATC treatment.

show abstract